Latest news with #RegeneronGeneticsCenter
Business Wire
12-06-2025
- Health
- Business Wire
Regeneron Genetics Center Selects Olink ® Explore HT for Landmark Proteomics Study of 200,000 Patient Samples
UPPSALA, Sweden--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced that the Regeneron Genetics Center ® (RGC™) has selected the Olink Explore HT proteomics platform for a large-scale proteomics investigation involving nearly 200,000 patient samples from the Geisinger Health Study that aims to unlock new insights into the dynamic biology and mechanisms of human disease. Regeneron Genetics Center selects the Olink Explore HT proteomics platform for a large-scale proteomics investigation that aims to unlock new insights into the dynamic biology and mechanisms of human disease. Share The Geisinger Health Study, characterized by deep phenotyping data, offers a unique opportunity to monitor proteomic changes at scale. RGC's established infrastructure is designed to manage large-scale projects and is built for the efficient execution of this ambitious endeavor. RGC's selection of Olink Explore HT follows the platform's selection for use in the UK Biobank Pharma Proteomics Project (UKB-PPP), the world's largest human proteomics study. The Geisinger Health Study aims to validate genetic hypotheses, solidify drug targets identified by RGC's world-class genomic sequencing operation, and discover novel disease biomarkers to improve drug development efficiencies. Olink Explore HT was chosen for its unparalleled scalability, high throughput, and superior specificity, all of which are essential for processing such a vast number of samples. "We are thrilled to partner with RGC on this groundbreaking project,' said Carl Raimond, president, proteomic sciences, Thermo Fisher Scientific. 'The selection of Olink Explore HT underscores its ability to deliver robust and reliable data at scale. This important work will accelerate the pace of biomarker discovery and contribute significantly to the advancement of precision medicine." RGC is a cutting-edge research organization focused on uncovering genetic and proteomic insights, ensuring superb data stewardship, and ultimately driving scientific advancements in preventing and treating human disease. The integration of Olink Explore HT into their workflow signifies another major step forward in their commitment to leveraging multi-omics data for improved outcomes. 'The Olink Explore HT platform has proven to be an invaluable tool in our pursuit of deeper biological understanding,' stated John Overton, Vice President at Regeneron Genetics Center. 'Its scalability and specificity are essential for handling the complexities of a project of this size. We believe this ambitious endeavor will yield transformative insights that will drive innovation in scientific discoveries.' The comprehensive mapping of protein levels across such a large population of patient samples represents a significant milestone in the field of proteomics, paving the way for future studies to advance our understanding of human health and disease. Learn more about Olink Explore HT. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit
Yahoo
19-05-2025
- Business
- Yahoo
Bankrupt 23andMe to be bought by pharmaceutical company Regeneron for $256 million
Genetic testing firm 23andMe is set to be acquired by drug company Regeneron Pharmaceuticals following its bankruptcy in March, the companies announced on Monday, May 19. Regeneron purchased the pioneering company for $256 million at bankruptcy auction with the intent of using its genomic data to fuel drug discovery, the company said in a Monday statement. More importantly to consumers who have privacy concerns during the proceedings, the pharmaceutical company promised to adhere to 23andMe's existing privacy policy, saying it will "prioritize the privacy, security and ethical use of 23andMe's customer data." "As a world leader in human genetics, Regeneron Genetics Center is committed to and has a proven track record of safeguarding the genetic data of people across the globe, and, with their consent, using this data to pursue discoveries that benefit science and society," Aris Baras, senior vice president and head of the Regeneron Genetics Center, said in a statement. 23andMe will continue to operate as a personal genomics service, which initially gained notoriety as the first company that enabled customers to submit DNA via a home swab and receive a digital map of their ancestry in return. The company filed for Chapter 11 bankruptcy in March and later agreed to allow a court-appointed overseer to monitor the use of genetic data collected from its 15 million users through the sale. Regeneron has agreed to allow an overseer to review its intended use of that data, as well. Since a data breach in October 2023 impacted 6.9 million customers, 23andMe has faced scrutiny from customers and lawmakers alike. In a statement on Monday, 23andMe chair of the Special Committee of the Board of Directors, said the company is "pleased to have reached a transaction that maximizes the value of the business and enables the mission of 23andMe to live on, while maintaining critical protections around customer privacy, choice and consent with respect to their genetic data." The statement also thanked Regeneron for extending job offers to employees of impacted departments. The sale is subject to the approval via bankruptcy proceedings and relevant regulatory bodies. It is expected to close in the third quarter. This article originally appeared on USA TODAY: Drug company Regeneron to buy bankrupt 23andMe. What about your data?
USA Today
19-05-2025
- Business
- USA Today
Bankrupt 23andMe to be bought by pharmaceutical company Regeneron for $256 million
Bankrupt 23andMe to be bought by pharmaceutical company Regeneron for $256 million Show Caption Hide Caption How to delete 23andMe data 23andMe has filed for bankruptcy. Here's how you can delete your data. Problem Solved Genetic testing firm 23andMe is set to be acquired by drug company Regeneron Pharmaceuticals following its bankruptcy in March, the companies announced on Monday, May 19. Regeneron purchased the pioneering company for $256 million at bankruptcy auction with the intent of using its genomic data to fuel drug discovery, the company said in a Monday statement. More importantly to consumers who have privacy concerns during the proceedings, the pharmaceutical company promised to adhere to 23andMe's existing privacy policy, saying it will "prioritize the privacy, security and ethical use of 23andMe's customer data." "As a world leader in human genetics, Regeneron Genetics Center is committed to and has a proven track record of safeguarding the genetic data of people across the globe, and, with their consent, using this data to pursue discoveries that benefit science and society," Aris Baras, senior vice president and head of the Regeneron Genetics Center, said in a statement. 23andMe will continue to operate as a personal genomics service, which initially gained notoriety as the first company that enabled customers to submit DNA via a home swab and receive a digital map of their ancestry in return. The company filed for Chapter 11 bankruptcy in March and later agreed to allow a court-appointed overseer to monitor the use of genetic data collected from its 15 million users through the sale. Regeneron has agreed to allow an overseer to review its intended use of that data, as well. Since a data breach in October 2023 impacted 6.9 million customers, 23andMe has faced scrutiny from customers and lawmakers alike. In a statement on Monday, 23andMe chair of the Special Committee of the Board of Directors, said the company is "pleased to have reached a transaction that maximizes the value of the business and enables the mission of 23andMe to live on, while maintaining critical protections around customer privacy, choice and consent with respect to their genetic data." The statement also thanked Regeneron for extending job offers to employees of impacted departments. The sale is subject to the approval via bankruptcy proceedings and relevant regulatory bodies. It is expected to close in the third quarter.
Entrepreneur
19-05-2025
- Business
- Entrepreneur
23andMe Is Selling All User Data to Drug Developer Regeneron
Genetic testing startup 23andMe, which filed for bankruptcy earlier this year, announced on Monday that it has agreed to sell the genetic data of its 15 million users, along with its core business, to drug developer Regeneron Pharmaceuticals. The acquisition, which followed a bankruptcy auction, is valued at $256 million and is expected to close in the third quarter of this year. Regeneron told 23andMe customers that it would adhere to 23andMe's privacy policy, which allows customers to request to delete their personal information. Related: 'Surprised and Disappointed': All Independent Board Members of 23andMe Resign, Leaving Only the CEO "We assure 23andMe customers that we are committed to protecting the 23andMe dataset," Aris Baras, head of the Regeneron Genetics Center, said in a press release. Baras explained that the Regeneron Genetics Center has experience with genetic data, processing the genetic information of nearly three million people in research studies since it was founded in 2013. Regeneron "shares 23andMe's founding vision of the power of genetics and data," Baras stated. Regeneron's acquisition includes 23andMe's personal genome service, which conducts DNA testing for genetic predispositions, ancestry, and traits based on a small saliva sample. Under the acquisition, 23andMe will continue its daily operations as a personal genomics service, but as a subsidiary of Regeneron, and continue to offer genetic testing. Anne Wojcicki. Photo by Cindy Ord/VF24/Getty Images for Vanity Fair Related: 'Difficult but Necessary': 23andMe Is Cutting 40% of Its Workforce The only part of 23andMe's business that the acquisition does not cover is its telehealth division, Lemonaid Health, which 23andMe plans to shut down. Company staff in divisions other than Lemonaid Health, numbering around 300 employees, will keep their jobs. The deal still has to be approved by the judge overseeing the bankruptcy in the U.S. Bankruptcy Court for the Eastern District of Missouri. 23andMe filed for bankruptcy in late March following a tumultuous few years. The company's reputation took a hit after a data breach in 2023 exposed the data of nearly seven million people, or about half of the company's users. 23andMe agreed to pay $30 million in September to settle a lawsuit about the breach, but data privacy remains a point of concern. 23andMe founder Anne Wojcicki, 51, resigned as 23andMe's CEO following news of the bankruptcy but continued to serve on the company's board of directors. Wojcicki, who co-founded 23andMe in 2006 and owns 49% of the company, said that she had resigned from the CEO role in order to be "in the best position" to bid for total ownership of the company. Wojcicki submitted a few rejected proposals to buy 23andMe, one in July 2024 and another in February to purchase all of the company's shares that she didn't already own in cash for $2.53 per share, for an equity value of $74.7 million. In September, all of 23andMe's independent directors resigned from the board due to strategic differences with Wojcicki. They have since been replaced. The company laid off 40% of its workforce, or over 200 people, in November to cut costs. 23andMe went public in 2021 and was valued at around $6 billion that year at its peak.
